Novel metabolic biomarkers related to sulfur-dependent detoxification pathways in autistic patients of Saudi Arabia

[1]  A. El-Ansary,et al.  Impaired plasma phospholipids and relative amounts of essential polyunsaturated fatty acids in autistic patients from Saudi Arabia , 2011, Lipids in Health and Disease.

[2]  A. El-Ansary,et al.  Plasma fatty acids as diagnostic markers in autistic patients from Saudi Arabia , 2011, Lipids in Health and Disease.

[3]  Manisha N. Patel,et al.  Respiration-dependent H2O2 Removal in Brain Mitochondria via the Thioredoxin/Peroxiredoxin System* , 2010, The Journal of Biological Chemistry.

[4]  A. Persico,et al.  Mitochondrial dysfunction in autism spectrum disorders: cause or effect? , 2010, Biochimica et biophysica acta.

[5]  R. Liu,et al.  N-acetylcysteine attenuates phosgene-induced acute lung injury via up-regulation of Nrf2 expression , 2010, Inhalation toxicology.

[6]  Pat Levitt,et al.  Evaluation, Diagnosis, and Treatment of Gastrointestinal Disorders in Individuals With ASDs: A Consensus Report , 2010, Pediatrics.

[7]  A. El-Ansary,et al.  Measurement of selected ions related to oxidative stress and energy metabolism in Saudi autistic children. , 2010, Clinical biochemistry.

[8]  A. El-Ansary,et al.  Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children. , 2009, Clinical biochemistry.

[9]  A. El-Ansary,et al.  Metabolic biomarkers related to energy metabolism in Saudi autistic children. , 2009, Clinical biochemistry.

[10]  Janet K. Kern,et al.  Biomarkers of environmental toxicity and susceptibility in autism , 2009, Journal of the Neurological Sciences.

[11]  A. González,et al.  Mitochondrial DNA haplogroup H structure in North Africa , 2009, BMC Genetics.

[12]  Jaquelyn B. McCandless,et al.  Low natural killer cell cytotoxic activity in autism: The role of glutathione, IL-2 and IL-15 , 2008, Journal of Neuroimmunology.

[13]  K. Aytemir,et al.  Serum elevated gamma glutamyltransferase levels may be a marker for oxidative stress in Alzheimer's disease , 2008, International Psychogeriatrics.

[14]  M. Atmaca,et al.  Antioxidant enzyme and malondialdehyde levels in patients with social phobia , 2008, Psychiatry Research.

[15]  Jie Bai,et al.  Thioredoxin as a neurotrophic cofactor and an important regulator of neuroprotection , 2004, Molecular Neurobiology.

[16]  A. Holmgren,et al.  Thioredoxin and related molecules--from biology to health and disease. , 2007, Antioxidants & redox signaling.

[17]  Stepan Melnyk,et al.  Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[18]  Jareen Meinzen-Derr,et al.  Elevated cytokine levels in children with autism spectrum disorder , 2006, Journal of Neuroimmunology.

[19]  S. Buyske,et al.  Analysis of case-parent trios at a locus with a deletion allele: association of GSTM1 with autism , 2006, BMC Genetics.

[20]  T P Stein,et al.  Increased excretion of a lipid peroxidation biomarker in autism. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[21]  H. Walach,et al.  Mercury and autism: accelerating evidence? , 2005, Neuro endocrinology letters.

[22]  S. Rhee,et al.  Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. , 2005, Free radical biology & medicine.

[23]  David W Gaylor,et al.  Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. , 2004, The American journal of clinical nutrition.

[24]  P. Montuschi,et al.  Isoprostanes: markers and mediators of oxidative stress , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  P. Brennan,et al.  GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high‐risk population , 2004, International journal of cancer.

[26]  S. Zoroglu,et al.  Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism , 2004, European Archives of Psychiatry and Clinical Neuroscience.

[27]  F. E. Yazbak.  Autism seems to be increasing worldwide, if not in London , 2004, BMJ : British Medical Journal.

[28]  C. McDougle,et al.  Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. , 2003, Pediatrics.

[29]  J. Sastre,et al.  Mitochondrial theory of aging: importance to explain why females live longer than males. , 2003, Antioxidants & redox signaling.

[30]  Dean P. Jones,et al.  Redox Potential of Human Thioredoxin 1 and Identification of a Second Dithiol/Disulfide Motif* , 2003, Journal of Biological Chemistry.

[31]  E. Bertini,et al.  Analysis of glutathione: implication in redox and detoxification. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[32]  G. Powis,et al.  Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. , 2003, Molecular cancer research : MCR.

[33]  J. F. White,et al.  Intestinal Pathophysiology in Autism , 2003, Experimental biology and medicine.

[34]  H. Savaş,et al.  Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[35]  H. Herken,et al.  Pathophysiological role of nitric oxide and adrenomedullin in autism , 2003, Cell biochemistry and function.

[36]  Inge-Marie Eigsti,et al.  A systems neuroscience approach to autism: biological, cognitive, and clinical perspectives. , 2003, Mental retardation and developmental disabilities research reviews.

[37]  O. Yorbik,et al.  Investigation of antioxidant enzymes in children with autistic disorder. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[38]  M. Chez,et al.  Double-Blind, Placebo-Controlled Study of L-Carnosine Supplementation in Children With Autistic Spectrum Disorders , 2002, Journal of child neurology.

[39]  M. Mora,et al.  Antioxidant and Pro-oxidant Effect of the Thiolic Compounds N -acetyl- l -cysteine and Glutathione against Free Radical-induced Lipid Peroxidation , 2002, Free radical research.

[40]  S. Bölte,et al.  The Relation Between General Cognitive Level and Adaptive Behavior Domains in Individuals with Autism with and Without Co-Morbid Mental Retardation , 2002, Child psychiatry and human development.

[41]  B. Deplancke,et al.  Redox control of the transsulfuration and glutathione biosynthesis pathways. , 2002, Current opinion in clinical nutrition and metabolic care.

[42]  Freya Q. Schafer,et al.  Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. , 2001, Free radical biology & medicine.

[43]  P. Klatt,et al.  Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. , 2000, European journal of biochemistry.

[44]  D. Cantor,et al.  The neurotoxic etiology of the autistic spectrum disorders: a replication study , 2000 .

[45]  G. Moore,et al.  Evidence of altered energy metabolism in autistic children , 1999, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[46]  Hall.  The role of glutathione in the regulation of apoptosis , 1999, European journal of clinical investigation.

[47]  D. Cantor,et al.  Autism: Xenobiotic Influences , 1998, Toxicology and industrial health.

[48]  V. Singh,et al.  Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism , 1996, Journal of Neuroimmunology.

[49]  B. Halliwell,et al.  Superoxide‐dependent depletion of reduced glutathione by L‐DOPA and dopamine. Relevance to Parkinson's disease , 1995, Neuroreport.

[50]  P. Emery,et al.  Sulfate metabolism is abnormal in patients with rheumatoid arthritis. Confirmation by in vivo biochemical findings. , 1994, The Journal of rheumatology.

[51]  J. Spollen,et al.  A preliminary trial of ascorbic acid as supplemental therapy for autism , 1993, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[52]  Nancy J. Minshew,et al.  A preliminary 31P MRS study of autism: Evidence for undersynthesis and increased degradation of brain membranes , 1993, Biological Psychiatry.

[53]  V. Singh,et al.  Antibodies to Myelin Basic Protein in Children with Autistic Behavior , 1993, Brain, Behavior, and Immunity.

[54]  L. Borjas,et al.  [Clinical heterogeneity of the autistic syndrome: a study of 60 families]. , 1992, Investigacion clinica.

[55]  D. Goldberg,et al.  Heat stability and kinetic properties of human serum glutathione reductase activity in various disease states. , 1981, Biochemical medicine.

[56]  B. Golse,et al.  [Alterations in two enzymes: superoxide dismutase and glutathion peroxidase in developmental infantile psychosis (infantile autism) (author's transl)]. , 1978, Revue neurologique.